DiaMedica Therapeutics Reports 200th Patient Enrolled in ReMEDy2 Trial
The company said the 200th patient has enrolled in its Phase 2/3 acute ischemic stroke trial of DM199.
Story updates
12:01:44 PM UTC
SquawkNews
DiaMedica Therapeutics reached the 200th patient in its ReMEDy2 Phase 2/3 AIS trial, triggering a DSMB interim analysis after 90-day follow-up. The readout is expected in Q1 2027 and may lead to sample size re-estimation or stopping for futility.Material DetailsContext by AI AnalystThis is a mid-tr…